Search - tctmd.com

Displaying 201 - 220 of 426

Sort: Relevancy | Date

Viper Peptides Explored Anew as Antiplatelet Drugs

News Daily News

Viper Peptides Explored Anew as Antiplatelet Drugs

Yael L. Maxwell

June 08, 2017

More Excess Bleeding and No Benefit With Triple Therapy After PCI, Meta-analysis Finds

News Daily News

More Excess Bleeding and No Benefit With Triple Therapy After PCI, Meta-analysis Finds

May 05, 2017

Live From Washington: ACC 2017, Day Two

News Conference News ACC 2017

Live From Washington: ACC 2017, Day Two

March 18, 2017

Faster Primary PCIs Linked to Higher Stent Thrombosis Risk With Bivalirudin

News Daily News

Faster Primary PCIs Linked to Higher Stent Thrombosis Risk With Bivalirudin

March 07, 2017

Rising Subdural Hematoma Rates Appear to Be Linked to Greater Use of Antithrombotics

News Daily News

Rising Subdural Hematoma Rates Appear to Be Linked to Greater Use of Antithrombotics

March 03, 2017

Higher Mortality Among TAVR Patients With Atrial Fibrillation Treated With Triple Therapy

News Conference News CRT 2017

Higher Mortality Among TAVR Patients With Atrial Fibrillation Treated With Triple Therapy

Michael O'Riordan

February 20, 2017

News Daily News

Best Anticoagulant in the TAVR Patient With A-fib? Small Study Makes Case for Apixaban

Michael O'Riordan

January 03, 2017

News Daily News

With No RCTs, Propensity-Score Matched Analysis Informs Choice Between Cangrelor and GPIs in the Cath Lab

Yael L. Maxwell

December 06, 2016

News Daily News

Tricky Population of Patients With A-fib Undergoing PCI Tackled in New Consensus Document

November 29, 2016

News Conference News AHA 2016

Ticagrelor Fails to Best Clopidogrel in Preventing CV Events in PAD Patients

Yael L. Maxwell

November 13, 2016

Controversy 5. Adjunctive Pharmacotherapy for TAVR: “Real World” Usage Patterns of Antiplatelet and Antithrombotic Agents

Presentation TCT 2016

Controversy 5. Adjunctive Pharmacotherapy for TAVR: Real World Usage Patterns of Antiplatelet and Antithrombotic Agents

Presenter: Raj Makkar, Lars Sondergaard, Luis Nombela-Franco

October 31, 2016

TCT 7: Relationship Between Traditional Risk Factors, Platelet Reactivity, and Thrombotic Events: A Mediation Analysis From ADAPT-DES

Presentation TCT 2016

TCT 7: Relationship Between Traditional Risk Factors, Platelet Reactivity, and Thrombotic Events: A Mediation Analysis From ADAPT-DES

Presenter: Dimitrios Alexopoulos, Laurent Bonello, Bjorn Redfors

October 31, 2016

TCT 8: Impact of Aspirin Resistance on Outcomes After Coronary Events

Presentation TCT 2016

TCT 8: Impact of Aspirin Resistance on Outcomes After Coronary Events

Presenter: Dimitrios Alexopoulos, Laurent Bonello, Christine Chung

October 31, 2016

TCT 6: Simultaneous Impact of Thrombotic and Bleeding Risks on Use of Novel P2Y12 Inhibitors in Contemporary PCI: Results From a Large Single-Center Registry

Presentation TCT 2016

TCT 6: Simultaneous Impact of Thrombotic and Bleeding Risks on Use of Novel P2Y12 Inhibitors in Contemporary PCI: Results From a Large Single-Center Registry

Presenter: Dimitrios Alexopoulos, Laurent Bonello, Usman Baber

October 31, 2016

TCT 5: Risks and Benefits of Dual Antiplatelet Therapy After Coronary Artery Bypass Graft Surgery: Insights From the ACUITY Trial

Presentation TCT 2016

TCT 5: Risks and Benefits of Dual Antiplatelet Therapy After Coronary Artery Bypass Graft Surgery: Insights From the ACUITY Trial

Presenter: Dimitrios Alexopoulos, Laurent Bonello, Ramin Ebrahimi

October 31, 2016

News Conference News TCT 2016

‘Encouraging’ Preliminary Results Seen With Novel, Polymer-Free, Drug-Filled Stent

October 31, 2016

Debate #2: Is LAA Closure Preferred First-line Treatment in Patients With Recent Stents or ACS? No – A Combination of Antiplatelet Agents and Warfarin/NOACs Shoud Be Tried First!

Presentation TCT 2016

Debate #2: Is LAA Closure Preferred First-line Treatment in Patients With Recent Stents or ACS? No A Combination of Antiplatelet Agents and Warfarin/NOACs Shoud Be Tried First!

Presenter: David R. Holmes Jr., Josep Rodés-Cabau, Freek W.A. Verheugt

October 30, 2016

Reversal of Chronic Anticoagulation: When, What, and How Effective?

Presentation TCT 2016

Reversal of Chronic Anticoagulation: When, What, and How Effective?

Presenter: Paul A. Gurbel, James A. Reiffel

October 30, 2016

Chronic Oral Anticoagulants: Limitations, Use Recommendations, and Investigational Agents

Presentation TCT 2016

Chronic Oral Anticoagulants: Limitations, Use Recommendations, and Investigational Agents

Presenter: Paul A. Gurbel, Christopher B. Granger

October 30, 2016

Antiplatelet Agents: Limitations, Use Recommendations, and Investigational Agents

Presentation TCT 2016

Antiplatelet Agents: Limitations, Use Recommendations, and Investigational Agents

Presenter: David J. Moliterno

October 30, 2016

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.